RxDoctor Payments Data

Blair Fennimore, MD

Gastroenterology · Aurora, CONPI 1316093925

Payments from drug & device makers

$3,004in general payments, 2019–2025

Across 17 payments — averaging $176.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Takeda Pharmaceuticals U.S.A., Inc.$3K
  • AbbVie$235
  • Braintree Laboratories, Inc.$129
  • Olympus America Inc.$65
  • Pfizer$16
  • Merck$14
$13,735in research payments, 2019–2025

Across 2 payments — averaging $6867.61 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Takeda Pharmaceuticals U.S.A., Inc.$14K

What the payments were for

  • Speaking & faculty fees$439%
  • Food & beverage$44388%
  • Education$163%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,004 in reported general payments places this provider in the 55th percentile of 304 gastroenterology providers in Colorado.

See all gastroenterology providers in Colorado

Medicare billing

Part B allowed, 2024
$45,646
Medicare patients
288
Services billed
412

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
StelaraUstekinumab37$1,265,975
XeljanzTofacitinib Citrate12$68,293
LinzessLinaclotide13$13,954
Mesalamine20$13,711
Mesalamine ErMesalamine14$9,818
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates53$3,439
Budesonide DrBudesonide14$2,013
Gavilyte-CPeg3350/Sod Sulf,bicarb,cl/Kcl67$1,142
Peg 3350-ElectrolyteSodium Chloride/Nahco3/Kcl/Peg21$619
Dicyclomine Hcl11$517
MethotrexateMethotrexate Sodium14$437
Azathioprine11$418
Pantoprazole Sodium18$263
Omeprazole19$238
Famotidine13$110

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerXeljanz$16$68,29312 claims
AbbVieLinzess$235$13,95413 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 304 gastroenterology providers in Colorado.

Other gastroenterology in Aurora

See the full list for Colorado

Where these figures come from

Is this you, or does something look wrong? →